306 related articles for article (PubMed ID: 17324489)
1. Cost-effectiveness analysis of inactivated virosomal subunit influenza vaccination in children aged 3-14 years from the provider and societal perspectives.
Navas E; Salleras L; Domínguez A; Ibáñez D; Prat A; Sentís J; Garrido P
Vaccine; 2007 Apr; 25(16):3233-9. PubMed ID: 17324489
[TBL] [Abstract][Full Text] [Related]
2. Economic benefits for the family of inactivated subunit virosomal influenza vaccination of healthy children aged 3-14 years during the annual health examination in private paediatric offices.
Salleras L; Navas E; Domínguez A; Ibáñez D; Prat A; Garrido P; Asenjo MA; Torner N
Vaccine; 2009 May; 27(25-26):3454-8. PubMed ID: 19200830
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of virosomal subunit influenza vaccine in preventing influenza-related illnesses and its social and economic consequences in children aged 3-14 years: a prospective cohort study.
Salleras L; Domínguez A; Pumarola T; Prat A; Marcos MA; Garrido P; Artigas R; Bau A; Brotons J; Bruna X; Català P; Carreras E; Cuadra D; Gatell A; Millet S; Oller J; Raga E
Vaccine; 2006 Nov; 24(44-46):6638-42. PubMed ID: 16842892
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of influenza vaccination of healthy children.
Salo H; Kilpi T; Sintonen H; Linna M; Peltola V; Heikkinen T
Vaccine; 2006 Jun; 24(23):4934-41. PubMed ID: 16678945
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States.
Luce BR; Nichol KL; Belshe RB; Frick KD; Li SX; Boscoe A; Rousculp MD; Mahadevia PJ
Vaccine; 2008 Jun; 26(23):2841-8. PubMed ID: 18462851
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of influenza vaccination in working-age cancer patients.
Avritscher EB; Cooksley CD; Geraci JM; Bekele BN; Cantor SB; Rolston KV; Elting LS
Cancer; 2007 Jun; 109(11):2357-64. PubMed ID: 17457827
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness and potential impact of rotavirus vaccination in the United States.
Widdowson MA; Meltzer MI; Zhang X; Bresee JS; Parashar UD; Glass RI
Pediatrics; 2007 Apr; 119(4):684-97. PubMed ID: 17403839
[TBL] [Abstract][Full Text] [Related]
9. Regional variation in the cost effectiveness of childhood hepatitis A immunization.
Jacobs RJ; Greenberg DP; Koff RS; Saab S; Meyerhoff AS
Pediatr Infect Dis J; 2003 Oct; 22(10):904-14. PubMed ID: 14551492
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.
Aballéa S; Chancellor J; Martin M; Wutzler P; Carrat F; Gasparini R; Toniolo-Neto J; Drummond M; Weinstein M
Value Health; 2007; 10(2):98-116. PubMed ID: 17391419
[TBL] [Abstract][Full Text] [Related]
11. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
[TBL] [Abstract][Full Text] [Related]
12. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
[TBL] [Abstract][Full Text] [Related]
13. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis.
Rothberg MB; Rose DN
Am J Med; 2005 Jan; 118(1):68-77. PubMed ID: 15639212
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of universal pneumococcal vaccination for infants in Italy.
Marchetti M; Colombo GL
Vaccine; 2005 Aug; 23(37):4565-76. PubMed ID: 15992969
[TBL] [Abstract][Full Text] [Related]
15. Could a federal program to promote influenza vaccination among elders be cost-effective?
Patel MS; Davis MM
Prev Med; 2006 Mar; 42(3):240-6. PubMed ID: 16480761
[TBL] [Abstract][Full Text] [Related]
16. Medicaid-based child restraint system disbursement and education and the vaccines for children program: comparative cost-effectiveness.
Goldstein JA; Winston FK; Kallan MJ; Branas CC; Schwartz JS
Ambul Pediatr; 2008; 8(1):58-65. PubMed ID: 18191783
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.
Zhou F; Santoli J; Messonnier ML; Yusuf HR; Shefer A; Chu SY; Rodewald L; Harpaz R
Arch Pediatr Adolesc Med; 2005 Dec; 159(12):1136-44. PubMed ID: 16330737
[TBL] [Abstract][Full Text] [Related]
18. Potential cost-effectiveness of annual influenza immunization for infants and toddlers: experience from Canada.
Skowronski DM; Woolcott JC; Tweed SA; Brunham RC; Marra F
Vaccine; 2006 May; 24(19):4222-32. PubMed ID: 16423432
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of adjuvanted influenza vaccination of healthy children 6 to 60 months of age.
Marchetti M; Kühnel UM; Colombo GL; Esposito S; Principi N
Hum Vaccin; 2007; 3(1):14-22. PubMed ID: 17245134
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of introducing the conjugated pneumococcal vaccine to routine free immunizations for infants in Lazio, Italy.
Giorgi-Rossi P; Merito M; Borgia P
Health Policy; 2009 Feb; 89(2):225-38. PubMed ID: 18639952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
